SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

Published:2019-10 Issue:10 Volume:14 Page:1839-1846
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Langer Corey J.,Redman Mary W.,Wade James L.,Aggarwal Charu,Bradley Jeffrey D.,Crawford Jeffrey,Stella Philip J.,Knapp Mark H.,Miao Jieling,Minichiello Katherine,Herbst Roy S.,Kelly Karen,Gandara David R.,Papadimitrakopoulou Vassiliki A.

Funder

Bristol-Myers Squibb

Genentech

Pfizer

AstraZeneca

Amgen

National Institutes of Health

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. Lung Master Protocol (Lung-MAP)—a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400;Herbst;Clin Cancer Res,2015

2. The phosphoinositide 3-kinase pathway;Cantley;Science,2002

3. Defining the role of mTOR in cancer;Guertin;Cancer Cell,2007

4. Mutation of the PIK3CA oncogene in human cancers;Karakas;Br J Cancer,2006

5. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression;Massion;Am J Respir Crit Care Med,2004

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma;Redox Biology;2024-09

2. Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions;Molecular Cancer;2024-08-10

3. Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400);Journal of Thoracic Oncology;2024-08

4. Current status of molecular diagnostics for lung cancer;Exploration of Targeted Anti-tumor Therapy;2024-06-27

5. MLIP and Its Potential Influence on Key Oncogenic Pathways;Cells;2024-06-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3